Novel targets for immunotherapy in glomerulonephritis

Biologics: Targets and Therapy

Volumn 2, Issue 3, 2008, Pages 531-545

  Foster, Mary H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glomerulonephritis; Goodpasture syndrome; Immunotherapy; Membranous nephropathy

Indexed keywords

EID: 73449100883     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s2764     Document Type: Review

References (126)

1. Abe K, Miyazaki M, Koji T, et al. 2001. Enhanced expression of complement C5a receptor mRNA in human diseased kidney assessed by in situ hybridization. Kidney Int, 60:137-46.
2. Abrahamson DR, Prettyman AC, Robert B, et al. 2003. Laminin-1 reexpression in Alport mouse glomerular basement membranes. Kidney Int, 63:826-34.
3. Aitman TJ, Dong R, Vyse TJ, et al. 2006. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature, 439:851-5.
4. Alarcon-Segovia D, Tumlin JA, Furie RA, et al. 2003. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum, 48:442-54.
5. Amital H, Heilweil M, Ulmansky R, et al. 2005. Treatment with a lamininderived peptide suppresses lupus nephritis. J Immunol, 175:5516-23.
6. Amital H, Heilweil-Harel M, Ulmansky R, et al. 2007. Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption. Rheumatology (Oxford), 46:1433-7.
7. Appel G, Nachman P, Hogan S, et al. 2002. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy (IMN): Preliminary baseline and pharmacokinetic (PK)/Pharmacodynamic (PD) data. J Am Soc Nephrol, 13:668A.
8. Bao L, Haas M, Boackle SA, et al. 2002. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol, 168:3601-7.
9. Bao L, Haas M, Kraus DM, et al. 2003. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol, 14:670-9.
10. Bao L, Osawe I, Puri T, et al. 2005. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol, 35:2496-506.
11. Bolland S, Ravetch J. 2000. Spontaneous autoimmune disease in Fcgamma. RIIB-deficient mice results from strain-specific epistasis. Immunity, 13:277-85.
12. Borza D, Bondar O, Todd P, et al. 2002. Quaternary organization of the goodpasture autoantigen, the alpha 3(IV) collagen chain. Sequestration of two cryptic autoepitopes by intrapromoter interactions with the alpha4 and alpha5 NC1 domains. J Biol Chem, 277:40075-83.
13. Borza DB, Bondar O, Colon S, et al. 2005. Goodpasture autoantibodies unmask cryptic epitopes by selectively dissociating autoantigen complexes lacking structural reinforcement: novel mechanisms for immune privilege and autoimmune pathogenesis. J Biol Chem, 280:27147-54.
14. Borza DB, Hudson BG, 2003. Molecular characterization of the target antigens of anti-glomerular basement membrane antibody disease. Springer Semin Immunopathol, 24:345-61.
15. Borza DB, Netzer KO, Leinonen A, et al. 2000. The goodpasture autoantigen. Identification of multiple cryptic epitopes on the NC1 domain of the alpha3 (IV) collagen chain. J Biol Chem, 275:6030-7.
16. Botto M, Dell'Agnola C, Bygrave AE, et al. 1998. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet, 19:56-9.
17. Boutaud AA, Kalluri R, Kahsai TZ, et al. 1996. Goodpasture syndrome: selective removal of anti-alpha 3 (IV) collagen autoantibodies. A potential therapeutic alternative to plasmapheresis. Exp Nephrol, 4:205-12.
18. Braun M, Davis AE, 3rd 1998. Cultured human glomerular mesangial cells express the C5a receptor. Kidney Int, 54:1542-9.
19. Briganti EM, Russ GR, McNeil JJ, et al. 2002. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med, 347:103-9.
20. Chen Z, Koralov SB, Kelsoe G. 2000. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. J Exp Med, 192:1339-52.
21. Clynes R, Dumitru C, Ravetch JV. 1998. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science, 279:1052-4.
22. Coresh J, Selvin E, Stevens LA, et al. 2007. Prevalence of chronic kidney disease in the United States. JAMA, 298:2038-47.
23. Couser WG. 1999. Glomerulonephritis. Lancet, 353:1509-15.
24. Couser W. 2005. Recurrent glomerulonephritis in the renal allograft: an update of selected areas. Exp Clin Transplant, 3:283-8.
25. Couser W, Steinmuller D, Stilmant M, et al. 1978. Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest, 62:1275-87.
26. Couser WG, Nangaku M. 2006. Cellular and molecular biology of membranous nephropathy. J Nephrol, 19:699-705.
27. Cybulsky AV, Quigg RJ, Salant DJ. 2005. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol, 289:F660-71.
28. Cybulsky A, Rennke H, Feintzeig I, et al. 1986. Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J. Clin Invest, 77:1096-107.
29. David M, Borza D, Leinonen A, et al. 2001. Hydrophobic amino acid residues are critical for the immunodominant epitope of the Goodpasture autoantigen. A molecular basis for the cryptic nature of the epitope. J Biol Chem, 276:6370-7.
30. Debiec H, Guigonis V, Mougenot B, et al. 2002. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med, 346:2053-60.
31. Debiec H, Nauta J, Coulet F, et al. 2004. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet, 364:1252-9.
32. Debiec H, Ronco P. 2007. Fetomaternal alloimmunization with antenatal glomerulopathies. Ann N Y Acad Sci, 1110:559-66.
33. Dirks JH, de Zeeuw D, Agarwal SK, et al. 2005. Prevention of chronic kidney and vascular disease: toward global health equity - the Bellagio 2004 Declaration. Kidney Int Suppl:S1-6.
34. Donauer J, Wilpert J, Geyer M, et al. 2006. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a single center experience. Xenotransplantation, 13:108-10.
35. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, et al. 2004. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol, 15:787-95.
36. Einav S, Pozdnyakova OO, Ma M, et al. 2002. Complement C4 is protective for lupus disease independent of C3. J Immunol, 168:1036-41.
37. Elliott MK, Jarmi T, Ruiz P, et al. 2004. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int, 65:129-38.
38. Fanciulli M, Norsworthy PJ, Petretto E, et al. 2007. FCGR3B copy number variation is associated with susceptibility to systemic, but not organspecific, autoimmunity. Nat Genet, 39:721-3.
39. Farquhar MG, Saito A, Kerjaschki D, et al. 1995. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol, 6:35-47.
40. Floto RA, Clatworthy MR, Heilbronn KR, et al. 2005. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med, 11:1056-8.
41. Foster MH. 2007. T cells and B cells in lupus nephritis. Semin Nephrol, 27:47-58.
42. Fujii T, Hamano Y, Ueda S, et al. 2003. Predominant role of FcgammaRIII in the induction of accelerated nephrotoxic glomerulonephritis. Kidney Int, 64:1406-16.
43. Furie R. 2006. Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheum Dis Clin North Am, 32:149-56.
44. Gasque P. 2004. Complement: a unique innate immune sensor for danger signals. Mol Immunol, 41:1089-98.
45. Hahn B, Singh R, La Cava A, et al. 2005. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosisresistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol, 175:7728-37.
46. Hahn BH, Singh RR, Wong WK, et al. 2001. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum, 44:432-41.
47. He C, Imai M, Song H, et al. 2005. Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol, 174:5750-7.
48. Hellmark T, Burkhardt H, Wieslander J. 1999. Goodpasture disease. Characterization of a single conformational epitope as the target of pathogenic autoantibodies. J Biol Chem, 274:25862-8.
49. Hogasen K, Jansen JH, Mollnes TE, et al. 1995. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest, 95:1054-61.
50. Huber-Lang M, Sarma JV, Zetoune FS, et al. 2006. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med, 12:682-7.
51. Hudson BG, Tryggvason K, Sundaramoorthy M, et al. 2003. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med, 348:2543-56.
52. Jansen JH, Hogasen K, Harboe M, et al. 1998. In situ complement activation in porcine membranoproliferative glomerulonephritis type II. Kidney Int, 53:331-49.
53. Javaid B, Quigg RJ. 2005. Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics? Kidney Int, 67:1692-703.
54. Kalluri R, Cantley L, Kerjaschki D, et al. 2000a. Reactive oxygen species expose cryptic epitopes associated with autoimmune Goodpasture syndrome. J Biol Chem, 275:20027-32.
55. Kalluri R, Danoff TM, Okada H, et al. 1997. Susceptibility to anti-glomerular basement membrane disease and Goodpasture Syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J Clin Invest, 100:2263-75.
56. Kalluri R, Torre A, Shield CF 3rd, et al. 2000b. Identification of alpha3, alpha4, and alpha5 chains of type IV collagen as alloantigens for Alport posttransplant anti-glomerular basement membrane antibodies. Transplantation, 69:679-83.
57. Kaneko Y, Nimmerjahn F, Madaio MP, et al. 2006a. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med, 203:789-97.
58. Kaneko Y, Nimmerjahn F, Ravetch JV. 2006b. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 313:670-3.
59. Kang HK, Michaels MA, Berner BR, et al. 2005. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol, 174:3247-55.
60. Kerjaschki D, Farquhar M. 1982. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci USA, 79:5557-61.
61. Kerjaschki D, Horvat R, Binder S, et al. 1987. Identification of a 400-kd protein in the brush borders of human kidney tubules that is similar to gp330, the nephritogenic antigen of rat Heymann nephritis. Am J Pathol, 129:183-91.
62. Kono H, Kyogoku C, Suzuki T, et al. 2005. FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet, 14:2881-92.
63. La Cava A, Ebling FM, Hahn BH. 2004. Ig-reactive CD4+CD25+ T cells from tolerized New Zealand Black x New Zealand White.F1 mice suppress in vitro production of antibodies to DNA. J Immunol, 173:3542-8.
64. La Cava A., Fang CJ, Singh RP, et al. 2005. Manipulation of immune regulation in systemic lupus erythematosus. Autoimmun Rev, 4:515-9.
65. Leenaerts PL, Hall BM, van Damme BJ, et al. 1995. Active Heymann nephritis in complement component C6 deficient rats. Kidney Int, 47:1604-1614.
66. Lin F, Salant DJ, Meyerson H, et al. 2004. Respective roles of decayaccelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. J Immunol, 172:2636-42.
67. Mackay M, Stanevsky A, Wang T, et al. 2006. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med, 203:2157-64.
68. McCoy RC, Johnson HK, Stone WJ, et al. 1982. Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis. Kidney Int, 21:642-52.
69. McGaha TL, Sorrentino B, Ravetch JV. 2005. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science, 307:590-3.
70. Meri S, Koistinen V, Miettinen A, et al. 1992. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med, 175:939-50.
71. Meyers KE, Kinniry PA, Kalluri R, et al. 1998. Human Goodpasture antialpha3 (IV)NC1 autoantibodies share structural determinants. Kidney Int, 53:402-7.
72. Mitchell DA, Pickering MC, Warren J, et al. 2002. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol, 168:2538-43.
73. Miwa T, Zhou L, Tudoran R, et al. 2007. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity. Mol Immunol, 44:139-46.
74. Morgan BP, Harris CL. 2003. Complement therapeutics; history and current progress. Mol Immunol, 40:159-70.
75. Nakamura A, Yuasa T, Ujike A, et al. 2000. Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J Exp Med, 191:899-906.
76. Netzer KO, Leinonen A, Boutaud A, et al. 1999. The goodpasture autoantigen. Mapping the major conformational epitope(s) of alpha3 (IV) collagen to residues 17-31 and 127-141 of the NC1 domain. J Biol Chem, 274:11267-74.
77. Nimmerjahn F, Bruhns P, Horiuchi K, et al. 2005. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity, 23:41-51.
78. Nimmerjahn F, Ravetch JV. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science, 310:1510-2.
79. Nimmerjahn F, Ravetch J. 2006. Fcgamma receptors: old friends and new family members. Immunity, 24:19-28.
80. Nimmerjahn F, Ravetch JV. 2007. Fc-receptors as regulators of immunity. Adv Immunol, 96:179-204.
81. Olson DL, Anand SK, Landing BH, et al. 1980. Diagnosis of hereditary nephritis by failure of glomeruli to bind anti-glomerular basement membrane antibodies. J Pediatr, 96:697-9.
82. Park SY, Ueda S, Hamano Y, et al. 1998. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J Clin Invest, 54:1229-38.
83. Paul E, Pozdnyakova OO, Mitchell E, et al. 2002. Anti-DNA autoreactivity in C4-deficient mice. Eur J Immunol, 32:2672-9.
84. Pickering MC, Cook HT, Warren J, et al. 2002. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet, 31:424-8.
85. Pickering MC, Warren J, Rose KL, et al. 2006. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA, 103:9649-54.
86. Ponticelli C. 2007. Membranous nephropathy. J Nephrol, 20:268-87.
87. Prodeus AP, Goerg S, Shen LM, et al. 1998. A critical role for complement in maintenance of self-tolerance. Immunity, 9:721-31.
88. Radeke HH, Gessner JE, Uciechowski P, et al. 1994. Intrinsic human glomerular mesangial cells can express receptors for IgG complexes (hFc gamma RIII-A) and the associated Fc epsilon RI gamma-chain. J Immunol, 153:1281-92.
89. Ravetch JV, Bolland S. 2001. IgG Fc receptors. Annu Rev Immunol, 19:275-90.
90. Reynolds J, Prodromidi EI, Juggapah JK, et al. 2005. Nasal administration of recombinant rat alpha3 (IV)NC1 prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J Am Soc Nephrol, 16:1350-9.
91. Reynolds J, Pusey CD. 2001. Oral administration of glomerular basement membrane prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J Am Soc Nephrol, 12:61-70.
92. Ricklin D, Lambris JD. 2007. Complement-targeted therapeutics. Nat Biotechnol, 25:1265-75.
93. Riemekasten G, Langnicke LD, Enghard P, et al. 2004. Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol, 173:5835-42.
94. Ronco P, Allegri L, Brianti E, et al. 1989. Antigenic targets in epimembranous glomerulonephritis. Experimental data and potential application in human pathology. Appl Pathol, 7:85-98.
95. Ronco PM, Ardaillou N, Verroust P, et al. 1994. Pathophysiology of the podocyte: a target and a major player in glomerulonephritis. Adv Nephrol Necker Hosp, 23:91-131.
96. Ronco P, Debiec H. 2007. Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men. Semin Immunopathol, 29:445-58.
97. Roozendaal R, Carroll M. C. 2007. Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev, 219:157-66.
98. Rudolph EH, Congdon KL, Sackey FN, et al. 2002. Humoral autoimmunity to basement membrane antigens is regulated in C57BL/6 and MRL/MpJ mice transgenic for anti-laminin Ig receptors. J Immunol, 168:5943-53.
99. Saito A, Pietromonaco S, Loo AK, et al. 1994. Complete cloning and sequencing of rat gp330/"megalin", a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci, USA. 91:9725-9.
100. Saus J, Wieslander J, Langeveld J, et al. 1988. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem, 263:13374-80.
101. Schulze M, Donadio JV, Pruchno CJ, et al. 1991. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int, 40:533-8.
102. Schwarting A. 2006. Genetic predisposition - is lupus nephritis a question of copy numbers? Nephrol Dial Transplant, 21:2378-9.
103. Sekine H, Reilly CM, Molano ID, et al. 2001. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol, 166:6444-51.
104. Sheerin NS, Springall T, Abe K, et al. 2001. Protection and injury: the differing roles of complement in the development of glomerular injury. Eur J Immunol, 31:1255-60.
105. Sheerin NS, Springall T, Carroll MC, et al. 1997. Protection against antiglomerular basement membrane GBM-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol, 110:403-9.
106. Smith RJ, Alexander J, Barlow PN, et al. 2007. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol, 18:2447-56.
107. Song H, He C, Knaak C, et al. 2003. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest, 111:1875-85.
108. Stoll ML, Price KD, Silvin CJ, et al. 2007. Immunization with peptides derived from the idiotypic region of lupus-associated autoantibodies delays the development of lupus nephritis in the SWR x NZB.F1 murine model. J Autoimmun, 29:30-7.
109. Susani M, Schulze M, Exner M, et al. 1994. Antibodies to glycolipids activate complement and promote proteinuria in passive Heymann nephritis. Am J Pathol, 144:807-19.
110. Tarzi RM, Davies KA, Robson MG, et al. 2002. Nephrotoxic nephritis is mediated by Fcgamma receptors on circulating leukocytes and not intrinsic renal cells. Kidney Int, 62:2087-96.
111. Timoshanko JR, Tipping PG. 2005. Resident kidney cells and their involvement in glomerulonephritis. Curr Drug Targets Inflamm Allergy, 4:353-62.
112. Toubi E, Kessel A, Shoenfeld Y. 2005. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol, 66:395-402.
113. Turnberg D, Botto M, Warren J, et al. 2003. CD59a deficiency exacerbates accelerated nephrotoxic nephritis in mice. J Am Soc Nephrol, 14:2271-9.
114. Turnberg D, Cook HT. 2005. Complement and glomerulonephritis: new insights. Curr Opin Nephrol Hypertens, 14:223-8.
115. US Renal Data System. 2007. ESRD incidence and prevalence. In USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. pp 81-98.
116. van Damme B, Fleuren G, Bakker W, et al. 1978. Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest, 38:502-10.
117. Wakayama H, Hasegawa Y, Kawabe T, et al. 2000. Abolition of anti-glomerular basement membrane antibody-mediated glomerulonephritis in FcRgamma-deficient mice. Eur J Immunol, 30:1182-90.
118. Wang XP, Fogo AB, Colon S, et al. 2005. Distinct epitopes for antiglomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3 (IV) collagen: a janus-faced antigen. J Am Soc Nephrol, 16:3563-71.
119. Wang Y, Hu Q, Madri JA, et al. 1996. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA, 93:8563-8.
120. Watanabe H, Garnier G, Circolo A, et al. 2000. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol, 15:786-94.
121. Wieslander J, Barr JF, Butkowski RJ, et al. 1984. Goodpasture antigen of the glomerular basement membrane: localization to noncollagenous regions of type IV collagen. Proc Natl Acad Sci USA, 81:3838-42.
122. Wilson CB. 1997. Immune Models of Glomerular Injury. In Neilson EG, Couser WG (Eds) Immunologic Renal Diseases. Philadelphia: Lippincott-Raven.
123. Wolfraim LA. 2006. Treating autoimmune diseases through restoration of antigen-specific immune tolerance. Arch Immunol Ther Exp (Warsz), 54:1-13.
124. Wu HY, Ward FJ, Staines NA. 2002. Histone peptide-induced nasal tolerance: suppression of murine lupus. J Immunol, 169:1126-34.
125. Zhang Y, Su SC, Hecox DB, et al. 2006. Anti-Goodpasture autoantibodies escape regulation in a novel Ig transgenic model. J Am Soc Nephrol, 17:86 abst.
126. Zipfel PF, Heinen S, Jozsi M, et al. 2006. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol, 43:97-106.